Trademark notice & manufacturer non-affiliation

GLP1 Samples is an independent editorial publication. We are not affiliated with, endorsed by, sponsored by, or otherwise connected to any pharmaceutical manufacturer, telehealth provider, or compounding pharmacy named on this site.

Trademark ownership

The following are registered trademarks of their respective owners. Our use of these marks is editorial, descriptive, and qualifies as nominative fair use under U.S. trademark law (e.g., New Kids on the Block v. News America Publishing, 971 F.2d 302 (9th Cir. 1992); Playboy Enterprises v. Welles, 279 F.3d 796 (9th Cir. 2002)).

• Ozempic®, Wegovy®, Rybelsus®, Saxenda®, NovoCare® — registered trademarks of Novo Nordisk A/S.
• Mounjaro®, Zepbound®, LillyDirect® — registered trademarks of Eli Lilly and Company.
• Other product, brand, and provider names referenced on this site are the property of their respective owners.

What our use is

We name these products to factually identify them, compare them against one another, summarize their FDA-approved indications, cite peer-reviewed clinical evidence about them (e.g., the SUSTAIN, STEP, SELECT, SURPASS, and SURMOUNT trial programs), and discuss publicly disclosed pricing programs (manufacturer savings cards, NovoCare Pharmacy, LillyDirect Self Pay). Naming the product is the only practical way to provide this comparison.

What our use is not

We do not claim or imply:

• That GLP1 Samples is an authorized representative, reseller, distributor, or partner of any manufacturer.
• That any manufacturer endorses, sponsors, or has reviewed our editorial content or rankings.
• That our recommendations carry the weight of a manufacturer's own clinical or regulatory guidance.
• That we are a licensed pharmacy, dispensary, healthcare provider, or telehealth platform.

No reproduction of brand assets

We do not reproduce manufacturer logos, packaging, marketing creative, or copyrighted patient-facing materials. The G1 monogram is the original trademark of GLP1 Samples / Theory Road. Any provider logos used on the site appear under license from the respective providers as part of our editorial listing program; manufacturer logos are not displayed.

Off-label and compounded references

We discuss off-label prescribing of Type 2 diabetes drugs (e.g., Ozempic, Mounjaro) for weight loss, and we discuss compounded preparations of semaglutide and tirzepatide. These references are factual and editorial. Off-label prescribing is a licensed clinician's decision under their professional judgment; compounded preparations are made by state-licensed 503A and FDA-registered 503B pharmacies under their own regulatory frameworks. We do not prescribe, dispense, recommend specific dosing, or operate any clinical or pharmacy service ourselves.

Reach us

If you represent a manufacturer or provider and you believe our use of a mark or statement requires correction, email legal@glp1samples.com. We respond within seven business days.

Last reviewed: 2026-04-25· GLP1 Samples Editorial & Theory Road General Counsel · Affiliate disclosure · Medical disclaimer